Literature DB >> 19377787

Association between apolipoprotein E genotype, serum lipids, and colorectal cancer in Brazilian individuals.

D R S Souza1, M A Nakazone, M A S Pinhel, R M Alvares, A C Monaco, A Pinheiro, C F D C Barros, P M Cury, G S Cunrath, J G Netinho.   

Abstract

We evaluated genetic variants of apolipoprotein E (APOE HhaI) and their association with serum lipids in colorectal cancer (CRC), together with eating habits and personal history. Eight-seven adults with CRC and 73 controls were studied. APOE*2 (rs7412) and APOE*4 (rs429358) were identified by polymerase chain reaction-restriction fragment length polymorphism. APOE gene polymorphisms were similar in both groups, but the epsilon4/epsilon4 genotype (6%) was present only in controls. The patients had reduced levels (mean +/- SD) of total cholesterol and low-density lipoprotein cholesterol fraction (180.4 +/- 49.5 and 116.1 +/- 43.1 mg/dL, respectively) compared to controls (204.2 +/- 55.6, P = 0.135 and 134.7 +/- 50.8 mg/dL; P = 0.330, respectively) indicating that they were not statistically significant after the Bonferroni correction. The APOE*4 allele was associated with lower levels of total cholesterol, low- and high-density lipoprotein cholesterol fraction and increased levels of very low-density lipoprotein cholesterol fraction and triglycerides only among patients (P = 0.014). There was a positive correlation between the altered lipid profile and increased body mass indexes in both groups (P < 0.010). Moreover, a higher rate of hypertension and overweight was observed in controls (P < 0.002). In conclusion, the presence of the epsilon4/epsilon4 genotype only in controls may be due to a protective effect against CRC. Lower lipid profile values among patients, even those on lipid-rich diets associated with the APOE*4 allele, suggest alterations in the lipid synthesis and metabolism pathways in CRC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19377787     DOI: 10.1590/s0100-879x2009000500001

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  7 in total

1.  Association between apolipoprotein E genotype and cancer susceptibility: a meta-analysis.

Authors:  R Anand; S S Prakash; R Veeramanikandan; Richard Kirubakaran
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-05       Impact factor: 4.553

2.  Causal relevance of circulating high-density lipoprotein cholesterol with cancer: a Mendelian randomization meta-analysis.

Authors:  Chunhua Yang; Geng Tian; Jia Mi; Xiaodan Wei; Xuri Li; Xianglin Li; Wenming Wang; Bin Wang
Journal:  Sci Rep       Date:  2015-03-30       Impact factor: 4.379

3.  Apolipoprotein E polymorphism and colorectal neoplasm: results from a meta-analysis.

Authors:  Yun Tian; Jirong Wang; Ying Ye; Liqun Sun; Yingrui Fan; Li Wang; Juan Li; Zhaoxia Wang; Keming Wang
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

4.  Association of apoE gene polymorphisms with lipid metabolism in renal diseases.

Authors:  Tianbiao Zhou; Hongyan Li; Hongzhen Zhong; Zhiqing Zhong; Shujun Lin
Journal:  Afr Health Sci       Date:  2020-09       Impact factor: 0.927

5.  Effects of APOE gene ε4 allele on serum lipid profiles and risk of cardiovascular disease and tumorigenesis in southern Chinese population.

Authors:  Caiyan Gan; Yinmei Zhang; Fei Liang; Xuemin Guo; Zhixiong Zhong
Journal:  World J Surg Oncol       Date:  2022-09-03       Impact factor: 3.253

6.  Apolipoprotein E epsilon 2 allele and low serum cholesterol as risk factors for gastric cancer in a Chinese Han population.

Authors:  Ranran Kang; Ping Li; Tingting Wang; Xinxiu Li; Zichen Wei; Zhenlian Zhang; Li Zhong; Longlong Cao; Michael G Heckman; Yun-Wu Zhang; Huaxi Xu; Changming Huang; Guojun Bu; Xiao-Fen Chen
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

Review 7.  Apolipoprotein: prospective biomarkers in digestive tract cancer.

Authors:  Yibo Zhang; Lu Zheng
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.